Cargando...
Chimeric Antigen Receptor-Engineered T Cells for the Treatment of Metastatic Prostate Cancer
Cancer immunotherapy was selected as the Breakthrough of the Year 2013 by the editors of Science, in part because of the successful treatment of refractory hematological malignancies with adoptive transfer of chimeric antigen receptor (CAR)-engineered T cells. Effective treatment of B cell leukemia...
Guardado en:
| Publicado en: | BioDrugs |
|---|---|
| Autores principales: | , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Springer International Publishing
2015
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4544486/ https://ncbi.nlm.nih.gov/pubmed/25859858 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40259-015-0122-9 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|